Immutep Limited
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Immutep Limited Immutep Limited is an Australia-based late clinical-stage biotechnology company that develops novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. The company offers a diversified portfolio of proprietary therapeutics, including its lead candidate eftilagimod alfa (efti or IMP321), a soluble LAG-3Ig fusion protein and antigen-presenting cell agonist for oncology indications such as first-line non-small cell lung cancer (TACTI-004 and INSIGHT-003 trials), first-line head and neck squamous cell carcinoma (TACTI-003), metastatic urothelial cancer (INSIGHT-005), soft tissue sarcoma (EFTISARC-NEO), and breast cancer (AIPAC-003 and EOC 202); IMP761, an agonist LAG-3 antibody for autoimmune diseases; IMP731, a depleting LAG-3 antibody for ulcerative colitis and psoriasis; and out-licensed LAG-3 candidates in combination therapies for solid tumors, blood cancers, triple-negative breast cancer, and melanoma. Immutep was founded in 1999 stemming from the discovery of LAG-3 by its Chief Scientific Officer Dr. Frédéric Triebel and maintains headquarters in Sydney, New South Wales, with global operations encompassing clinical trials across Australia, Europe, and the United States; it retains worldwide rights to its key assets excluding mainland China, Hong Kong S.A.R., Macao S.A.R., and Taiwan for efti, where rights are licensed to EOC Pharma for potential milestone and royalty payments. In recent developments, Immutep met the primary endpoint in the EFTISARC-NEO Phase II trial evaluating neoadjuvant efti in soft tissue sarcoma, with data presented at ESMO Congress 2025 and highlighted in an oral presentation at CTOS 2025; completed FDA Project Optimus requirements confirming 30mg efti as the optimal biological dose for its oncology pipeline; received positive FDA feedback on late-stage development of efti in head and neck cancer for patients with CPS <1; announced an update advancing the TACTI-004 (KEYNOTE-F91) Phase III trial in first-line NSCLC; and entered a research collaboration with the George Washington University Cancer Center to evaluate neoadjuvant efti. The company maintains strategic clinical trial collaborations and supply agreements with MSD (Merck & Co., Inc.) for KEYTRUDA combinations, Merck KGaA for BAVENCIO, and Novartis for multiple out-licensed programs where Novartis funds development and Immutep receives milestones and royalties; additional partnerships include EOC Pharma and investigator-initiated trials by institutions such as the Institute of Clinical Cancer Research IKF and Maria Skłodowska-Curie National Research Institute of Oncology.
Company News
Prima BioMed (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average – What’s Next?
Immutep Receives ~A$0.86 Million R&D Tax Incentive
Short Interest in Prima BioMed Ltd (NASDAQ:IMMP) Decreases By 36.4%
Prima BioMed (NASDAQ:IMMP) Stock Crosses Above 50 Day Moving Average – Should You Sell?
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP
Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm
Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors
Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm